Hotchkiss

Scardina Joins GetMed Staffing as CEO

Retrieved on: 
Thursday, September 8, 2022
Aureus, Linda, View, Multimedia, Leadership, Knowledge, Hotchkiss, Woman, Growth, Industry, Management, Scardina

OMAHA, Neb., Sept. 8, 2022 /PRNewswire/ -- GetMed Staffing (Omaha, Nebraska) is thrilled to welcome Dan Scardina to the team as Chief Executive Officer.

Key Points: 
  • OMAHA, Neb., Sept. 8, 2022 /PRNewswire/ -- GetMed Staffing (Omaha, Nebraska) is thrilled to welcome Dan Scardina to the team as Chief Executive Officer.
  • Scardina brings 16 years of leadership experience in healthcare staffing and a vast array of expertise.
  • Highlighting his career success as Sr Management at Aureus Medical Group, Chief Sales Officer at Fusion Medical Staffing, and President of Fusion Marketplace and Fusion Workforce Solutions.
  • Founded in 2018, GetMed Staffing is a women & diversity-owned healthcare staffing agency with over 40 years of leadership and recruiting experience.

Global Automotive Drive Shafts Market to Reach $7.5 Billion by 2026

Retrieved on: 
Monday, March 21, 2022
Carbon, CAGR, Steel, Forecasting, Research, Carbon-fiber-reinforced polymers, Noise, Inorganic polymer, OEM, GDP, Car, Timken Company, Attention, Efficiency, Players, Torque, Marketing, American Axle, Industry, Income, Commercial vehicle, Vibration, GKN, Growth, Internet, Intelligence, SAN, Adoption, Hotchkiss, Safety, GIA, COVID-19, Nature, Renewable energy, Cardan, Aluminium, Others

SAN FRANCISCO, March 21, 2022 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Automotive Drive Shafts - Global Market Trajectory & Analytics" .

Key Points: 
  • SAN FRANCISCO, March 21, 2022 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Automotive Drive Shafts - Global Market Trajectory & Analytics" .
  • The global market for automotive drive shafts is expected to move ahead swiftly supported by a recovering automotive industry and implementation of stringent regulations regarding fuel efficiency and environmental protection.
  • Amid the COVID-19 crisis, the global market for Automotive Drive Shafts estimated at US$6 Billion in the year 2022, is projected to reach a revised size of US$7.5 Billion by 2026, growing at a CAGR of 5.4% over the analysis period.
  • The U.S. Market is Estimated at $1.1 Billion in 2022, While China is Forecast to Reach $1.8 Billion by 2026
    The Automotive Drive Shafts market in the U.S. is estimated at US$1.1 Billion in the year 2022.

Enveric Biosciences and University of Calgary Collaborate on a Groundbreaking Clinical Trial for EVM-101 in Cancer Related Distress

Retrieved on: 
Thursday, February 17, 2022
NASDAQ, Cumming School of Medicine, Psychotherapy, Collection, Patient, Cancer, CRD, Department, Company, Prevalence, Education, Brain, SEC, Phrase, IMPACT, Forward-looking statement, U.S. Securities and Exchange Commission, University of Calgary Faculty of Law, Security (finance), DOI, Budget, University, Clinical trial, CQD, 2009–10 Calgary Flames season, Health Canada, Anxiety, Demoralization, Annual report, Intention, Calgary Flames, Institute, Mental health, Peter L. Berger, Distress, Disorder, Grammatical mood, Mood disorder, PTSD, Marketing, Hotchkiss, Disease, The Company, Research, Coronavirus, HBI, Nature, COVID-19, Program, Pharmacotherapy, Drug development, Pharmaceutical industry, Medical device, Risk management, Medicine

Approximately 50% of cancer patients report clinical levels of psychological distress having depressed mood, anxiety, demoralization, stress-induced clinical manifestations, and reduced quality of life1.

Key Points: 
  • Approximately 50% of cancer patients report clinical levels of psychological distress having depressed mood, anxiety, demoralization, stress-induced clinical manifestations, and reduced quality of life1.
  • Up to 40% of cancer patients meet the criteria for a mood disorder requiring treatment2.
  • The EVM-101 study will directly assess the core features of CRD that are most affected and amenable to improvement following a psilocybin-based treatment.
  • Patient enrollment in the clinical trial is expected to begin late in 2022 or early in 2023.